Back to Clinical Trials Overview

Your search for "Infectious Diseases" returned 20 results:


Characterization of Acute HCV Infection
Principal Investigator(s): Fierer, Daniel S

A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study toInvestigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection
Principal Investigator(s): Rita Agarwal

Management Practices and the Risk of Infection Following Cardiac Surgery
Principal Investigator(s): Gelijns, Annetine

Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV
Principal Investigator(s): David Ferris

A randomized double-blind controlled evaluation of tenofovir DF versus adefovir dipivoxil for the treatment of presumed pre-core mutant chronic hepatitis B
Principal Investigator(s): Odin, Joseph A

A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Ponni Perumalswami

The Epidemiology of Ventricular Assist Device-Related Infections
Principal Investigator(s): Parides, Michael

Simeprevir (SMV)+Sofosbuvir (SOF) with or without Ribavirin (RBV) for Interferon-intolerant or ineligible (IFN-II) Patients with Chronic Hepatitis C (CHC)
Principal Investigator(s): Ritu Agarwal

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis
Principal Investigator(s): Meena Bansal

A Randomized Open-Label Multicenter Study to Evaluate the Efficacy Safety and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3
Principal Investigator(s): Ponni Perumalswami

A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor
Principal Investigator(s): Meena Bansal

The effect of non-ulcerative sexually transmitted infections on cervico-vaginal microbes and cervico-vaginal immune response
Principal Investigator(s): Sperling, Rhoda S, MD

Intracellular Antivirals:New Direction in HIV Control
Principal Investigator(s): Simon, Viviana

Efficacy & Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock
Principal Investigator(s): Oropello, John M

Studies of Ocular Complications of AIDS
Principal Investigator(s): Jabs, Douglas A

A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial
Principal Investigator(s): Ponni Perumalswami

Cervical, Anal & Oral HPV Persistence/Adolescent Girls
Principal Investigator(s): Diaz, Angela MD, MPH

A Long Term Follow-up Registry Study for Subjects Who Achieve A Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Ponni Perumalswami

An Open-Label Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
Principal Investigator(s): Douglas Dieterich

A Phase 2 Randomized Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the treatment of subjects with chronic hepatitis B and who are currently not on treatment
Principal Investigator(s): Jennifer Leong